Onglyza
[vc_row triangle_shape="no"][vc_column width="2/3"][vc_row_inner css=".vc_custom_1485393882049{padding-bottom: 43px !important;}"][vc_column_inner][vc_column_text css=".vc_custom_1492487256726{margin-top: 10px !important;margin-bottom: 5px !important;}"] Onglyza Lawsuit [/vc_column_text][vc_column_text] Onglyza, also known as saxagliptin, and kombiglyze CR (saxagliptin and metformin) and both forms of a new class of diabetic drug referred to as DPP-4 inhibitors. Onglyza managed to gain approval from the FDA in spite of many initial concerns regarding its cardiovascular safety. Anyone who has been harmed by the substance may be entitled to compensation. The concerns surrounding Onglyza were mirrored in a post-marketing safety study which revealed that the substance was correlated with an increased risk of heart failure and even death. Our attorneys are now discussing...
Continue reading